Associated Papers
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Estupiñán HY et al.
Leukemia, 2021
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.
Sedlarikova L et al.
Frontiers in Oncology, 2020
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Wang S et al.
Jci Insight, 2019
Select a paper to view details